Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.070
-0.040 (-3.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
November 02, 2023
Via
ACCESSWIRE
Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
November 01, 2023
Via
ACCESSWIRE
Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
October 30, 2023
Via
ACCESSWIRE
Jaguar Health to Present November 1st at Emerging Growth Conference
October 26, 2023
Via
ACCESSWIRE
Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
October 23, 2023
Via
ACCESSWIRE
Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
October 19, 2023
Via
ACCESSWIRE
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
September 14, 2023
Via
ACCESSWIRE
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
September 13, 2023
Via
ACCESSWIRE
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
September 11, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
October 18, 2023
Via
ACCESSWIRE
Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
October 12, 2023
Via
ACCESSWIRE
Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
October 10, 2023
Via
ACCESSWIRE
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
September 28, 2023
Via
ACCESSWIRE
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
September 27, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
September 26, 2023
Via
ACCESSWIRE
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
August 24, 2023
Via
ACCESSWIRE
Jaguar Health Reports Second Quarter 2023 Financial Results
August 14, 2023
Via
ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
August 10, 2023
Via
ACCESSWIRE
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
September 21, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
September 12, 2023
Via
ACCESSWIRE
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
September 07, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – Jaguar Health Inc. (NASDAQ: JAGX) Announces Investor Engagement Campaign with B2i Digital
September 05, 2023
Via
Investor Brand Network
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
August 30, 2023
Via
ACCESSWIRE
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
August 28, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
August 17, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
August 16, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
August 09, 2023
Via
ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
August 08, 2023
Via
ACCESSWIRE
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
August 07, 2023
Via
ACCESSWIRE
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
August 03, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.